AOD-9604: What It Is, How It Works, and Which Labs to Track

Medical disclaimer: The information in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Lab results and reference ranges vary by individual, lab, age, sex, and health history. Always consult a qualified healthcare provider before making any decisions about your health, medications, supplements, or lab testing. LabHealthCharts is a data visualization tool — it organizes and displays your lab data, it does not interpret your results or provide medical guidance.

A peptide fragment with a specific target

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH) — specifically amino acids 176 to 191. Researchers isolated this fragment because the full hGH molecule does both metabolic work (fat breakdown) and anabolic work (tissue growth and IGF-1 stimulation). AOD-9604 was designed to keep the lipolytic activity while removing the growth-promoting effects. In plain terms: it targets a narrow piece of the fat-regulation pathway without triggering the broader hormonal cascade that full growth hormone sets off.

That design choice matters for the lab picture. Unlike GH secretagogues such as ipamorelin or CJC-1295, AOD-9604 does not meaningfully raise IGF-1 levels in most published research. That distinction separates it from many other peptides in the metabolic and fat-loss category and changes which biomarkers are relevant to watch — and why.

You can read the full educational overview of AOD-9604 on the LabHealthCharts AOD-9604 page. The rest of this article focuses on the research and on which blood markers people commonly track when exploring its effects.

What the research actually says about mechanism and effect

AOD-9604 stimulates lipolysis — the breakdown of stored fat — and inhibits lipogenesis — the conversion of carbohydrates into new fat. Animal studies published in the 1990s and 2000s were the primary early evidence base. A series of experiments in obese mice showed significant reductions in body fat compared to controls, without the blood glucose or IGF-1 changes typically associated with full hGH. One frequently cited early study appeared in the International Journal of Obesity and reported reduced adiposity in diet-induced obese mice given the hGH fragment.

Human trials are more limited. Metabolic Pharmaceuticals (Australia) ran Phase I and Phase II trials in the early 2000s examining oral and injectable forms. A Phase IIb trial in overweight adults reported modest weight loss over 12 weeks but did not show statistically significant differences from placebo at the primary endpoint in at least one analysis. A summary of the human trial program appears in a review published in Regulatory Toxicology and Pharmacology. The compound received GRAS (Generally Recognized As Safe) status from the US FDA for food use, but it has not received approval as a drug in any major jurisdiction as of this writing.

Important study limitation: most positive data comes from animal models or small, industry-sponsored human trials. That does not make the research useless, but it does mean the effect sizes and clinical meaning in humans remain less established than for pharmaceutically approved weight-loss agents. Treat the evidence as preliminary.

Why IGF-1 is less relevant here than with other GH-axis peptides

IGF-1 (insulin-like growth factor 1) is the primary downstream marker for growth hormone activity. When you stimulate GH release — whether through sleep, exercise, or secretagogue peptides — the liver responds by producing more IGF-1. That is the signal most people track when using GH-axis compounds.

AOD-9604 appears to bypass the GH receptor pathway that triggers IGF-1 production. The fragment interacts with fat cells through a different mechanism, which is precisely what its designers intended. Published animal and human data consistently show that AOD-9604 does not significantly elevate serum IGF-1 at doses studied — a finding confirmed in a clinical pharmacology summary in the Annals of Clinical and Laboratory Science. So on your lab sheet: if you are already tracking IGF-1 for other reasons, it remains worth monitoring as a baseline reference, but a flat IGF-1 reading while using AOD-9604 is consistent with the research and does not suggest the compound is inactive.

Compare that to compounds like tesamorelin or ipamorelin, where rising IGF-1 is part of how researchers confirm the compound is doing what it is supposed to do. AOD-9604 tells a different lab story, and the metabolic markers take center stage.

The biomarkers most worth watching

Because AOD-9604's proposed mechanism runs through fat metabolism rather than the GH–IGF-1 axis, the most informative lab picture is a metabolic panel tracked over time. Here is what to pay attention to and why.

Fasting glucose and insulin

Full-dose hGH often raises blood glucose because it antagonizes insulin signaling. AOD-9604, by design, is not supposed to carry that risk. Human and animal studies have consistently shown no significant change in fasting glucose or insulin sensitivity — an important safety signal that researchers specifically measured in the trial program.

In practice: a fasting glucose panel (ideally paired with a fasting insulin level) provides a clear before-and-after picture of whether glucose metabolism has shifted. The reference range for fasting glucose used at major US labs is typically 70 to 99 mg/dL (3.9 to 5.5 mmol/L); fasting insulin is more variable by lab but generally 2 to 20 µIU/mL. A HOMA-IR calculation (glucose × insulin ÷ 405) can give a rough index of insulin resistance — a value below 2.0 suggests normal sensitivity in most reference frameworks, though some clinicians use a threshold of 1.5 for a tighter definition of optimal.

Triglycerides and fasting lipid panel

If AOD-9604 reduces fat mass and inhibits lipogenesis, a plausible downstream signal is lower serum triglycerides over time. Triglycerides (TG) are the form in which dietary energy circulates and is stored as fat; high levels (above 150 mg/dL in most US lab ranges) are associated with metabolic dysfunction and cardiovascular risk.

A full fasting lipid panel — total cholesterol, LDL, HDL, and triglycerides — gives context. Triglycerides respond quickly to dietary changes and weight loss, so they are a sensitive early signal. HDL cholesterol (the 'good' lipoprotein) typically rises as metabolic health improves. LDL and total cholesterol tend to be slower movers. Tracking all four across several draws, separated by 8 to 12 weeks, gives a real trend rather than random noise.

Body composition proxies on labs

Blood tests do not directly measure fat mass, but a few markers can shift when body composition changes. Creatinine, for example, is a byproduct of muscle metabolism — people with more lean mass tend to have higher creatinine levels. If fat decreases and muscle is preserved, creatinine should remain stable or rise slightly. If muscle is lost along with fat (a risk in any caloric deficit), creatinine may fall. The kidneys clear creatinine, so eGFR (estimated glomerular filtration rate) is linked to it — a rising creatinine does not mean kidney trouble in a person who has added muscle.

This is the same parsing challenge that arises during GLP-1 protocols, where rapid weight loss can make eGFR look artificially better because falling muscle mass reduces the creatinine load. Worth keeping an eye on when any body-recomposition strategy is in play.

Liver enzymes (ALT and AST)

ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are markers of liver cell stress. Significant fat loss can, in some cases, transiently stress the liver as stored lipids mobilize. More importantly, if someone is combining AOD-9604 with other compounds — stimulants, anabolic agents, alcohol, or hepatotoxic supplements — liver enzyme monitoring is a straightforward safety check. Standard reference ranges: ALT typically 7 to 56 U/L; AST typically 10 to 40 U/L (ranges vary by lab and sex). A result persistently above twice the upper limit of normal warrants attention and a conversation with a clinician.

HbA1c as a medium-term glucose average

Hemoglobin A1c (HbA1c) reflects average blood glucose over the preceding 8 to 12 weeks and is not affected by a single meal or an off day of eating. For anyone tracking metabolic markers over a multi-month protocol, it adds a layer of stability that fasting glucose alone cannot provide. Normal range is below 5.7% at most US labs; prediabetes is 5.7 to 6.4%; diabetes is 6.5% and above. A slow downward trend in HbA1c over several panels is meaningful; a single low reading is not.

Holistic context: why fat metabolism is not just about the scale

Metabolic health shows up across multiple organ systems at once. Adipose tissue is not inert storage; it produces inflammatory signals (adipokines), affects sex hormone balance, and modulates insulin sensitivity. When fat mass changes, a cascade of downstream effects follows — which is exactly why a single body-weight number misses most of the story, and why labs tell you more.

For example, high triglycerides alongside low HDL and elevated fasting insulin form a cluster sometimes called the 'lipid triad' of insulin resistance — a pattern associated with cardiovascular and metabolic risk independent of LDL. If a fat-loss intervention is working metabolically, that triad tends to move together and improve together. Tracking each marker on its own misses that pattern; seeing them on a longitudinal chart makes the cluster visible.

Sex and age also shape the baseline picture. Triglycerides tend to be higher in men than women on average; HDL targets differ by sex; insulin sensitivity typically declines with age. A 45-year-old man and a 28-year-old woman on the same protocol may show different lab trajectories for structural reasons that have nothing to do with the compound. Context from a clinician who knows your history is not optional — it is the interpretation layer that a chart alone cannot provide.

For further reading on how lipid markers interact and what the research says about moving them with dietary and lifestyle strategies, see the LabHealthCharts research library — including coverage of Lp(a), a cardiovascular risk marker that is largely genetic and rarely moved by metabolic interventions.

Regulatory status and what it means for how to read this research

AOD-9604 is not an approved pharmaceutical drug in the United States, Europe, or Australia. The FDA granted it GRAS status for use as a food ingredient, but that designation applies to safety at food-use levels — it is not equivalent to drug approval or a clinical endorsement of the mechanism. The compound is sold in various research and supplement contexts, but how it is sold and what oversight applies varies by jurisdiction.

A 2020 review in the Journal of Peptide Science examined the broader landscape of hGH fragment peptides in research and clinical contexts, noting that the gap between animal data and human outcomes remains a central challenge across this class. Users tracking their own response through blood work are, in effect, generating their own small N=1 longitudinal dataset — which is valuable, but requires careful interpretation and clinical oversight.

This is also an area where the 'one blood draw is a snapshot' principle applies with particular force. Metabolic markers fluctuate with diet, sleep, stress, and activity in ways that dwarf the effect sizes seen in the AOD-9604 trial data. A single fasting glucose of 92 mg/dL after six weeks of use tells you much less than four glucose readings across six months, plotted against what else changed in that period.

Tracking your metabolic panel over time: where longitudinal data changes everything

The metabolic markers discussed above — fasting glucose, insulin, triglycerides, HDL, HbA1c, liver enzymes — are not single-point measurements. They fluctuate, trend, and tell different stories at different points in a protocol or in a person's life. Fasting glucose on a high-stress week is not the same story as fasting glucose on a stable week, and neither reading alone tells you which one it is. Triglycerides after a weekend of eating differ from triglycerides on a controlled testing day. The trend across multiple draws — same conditions, same lab, consistent timing — is where actual signal lives.

LabHealthCharts is built for exactly this kind of longitudinal metabolic tracking. Upload your lab PDFs from Quest, LabCorp, or other major formats, and the AI-assisted extraction pulls your glucose, lipids, liver enzymes, and more than 100 other biomarkers into structured, time-ordered charts. Instead of comparing a printout from three months ago with today's result in your head, you see the actual line — direction, rate of change, and how related markers moved together.

That is useful for anyone tracking metabolic health in general, and it becomes more useful when a protocol adds a new variable. You can see whether triglycerides shifted before or after a change, whether fasting glucose has been stable for six months or quietly drifting, and whether HbA1c tells a different story than isolated glucose readings. LabHealthCharts organizes and visualizes that data — your clinician is still the person who interprets what the trend means for your individual health.

The membership is $79 per year (subscription required for uploads and chart access). If you want to start plotting your metabolic panel as a running history rather than a stack of PDFs, upload your labs and chart your metabolic panel over time at app.labhealthcharts.com. You can also explore the metabolic and fat-loss peptide category for more context on AOD-9604 and related compounds.

Key Takeaways

AOD-9604 is a C-terminal fragment of human growth hormone (amino acids 176–191), designed to stimulate fat breakdown without activating the GH receptor pathway that raises IGF-1 or disrupts blood glucose. The research base is primarily animal studies and early-phase human trials, with limited large-scale clinical data. Published human trials showed modest weight effects that did not always reach statistical significance versus placebo. The compound has FDA GRAS status for food use but is not an approved drug.

The most relevant biomarkers to track alongside AOD-9604 are fasting glucose, fasting insulin (and HOMA-IR), triglycerides, HDL cholesterol, HbA1c, and liver enzymes (ALT/AST). IGF-1 is worth including as a baseline reference but is not expected to rise significantly with this compound, which distinguishes it from GH secretagogues. Creatinine and eGFR are worth monitoring as body composition changes, since muscle mass shifts affect creatinine independent of kidney function.

Single blood draws are poor tools for evaluating any metabolic intervention. The meaningful signal is direction over time: are triglycerides trending down? Is fasting insulin stable or improving? Is HbA1c holding steady? Repeating a metabolic panel at 8 to 12 week intervals and viewing results on a longitudinal chart turns disconnected snapshots into an actual picture. Bring those trends to a clinician who can interpret them in the full context of your health history — that is where individual interpretation belongs.